Please login to the form below

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Guidelines RSS feed

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

Latest from PMLiVE on NICE, the SMC and the AWMSG

NICE knocks back Novartis’ oral MS drug Mayzent in draft guidance

25 Jun 2020
In the draft guidance, the NICE committee acknowledge the clinical effectiveness of Mayzent, but ultimately concluded that RRMS treatments were not relevant comparators for cost-effectiveness analysis. ... But NICE, together with the drug manufacturers

Celgene’s Revlimid scores NICE approval in follicular lymphoma

27 Feb 2020
New ‘chemotherapy-free’ treatment for patients with limited options. Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication ... for Health

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

17 Feb 2020
The SMC evaluated Crysvita under the ultra-orphan pathway, a new system for the consideration of novel treatments for extremely rare diseases. ... After three years, the SMC will review the new evidence and make a final decision on its routine use on NHS

NICE turns down Keytruda/Inlyta combo for kidney cancer

12 Feb 2020
Cost-effectiveness agency says the long-term benefit is uncertain. NICE has said that the recently-approved combination of Merck &Co/MSD’s Keytruda with Pfizer’s Inlyta shouldn’t be ... The Keytruda/Inlyta combination was approved by the EMA for

NICE plans to widen the net for data it uses in guidance

5 Feb 2020
Plans to include electronic health records and real-world evidence. UK cost-effectiveness body NICE has said it intends to use a broader range of data and analytics in the formulation ... The plan – originally proposed in principle last month – has

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk